与JAK2V617F突变相关的红细胞增多症在慢性粒细胞白血病治疗期间出现。 - Suppr

Suppr

超能文献

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

作者信息

Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K

出版信息

Leukemia. 2007 May;21(5):1103-4. doi: 10.1038/sj.leu.2404591. Epub 2007 Feb 15.

DOI:10.1038/sj.leu.2404591

PMID:17301812

Abstract

摘要

相似文献

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

Leukemia. 2007 May;21(5):1103-4. doi: 10.1038/sj.leu.2404591. Epub 2007 Feb 15.

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21.

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.

Leuk Res. 2009 Nov;33(11):e212-3. doi: 10.1016/j.leukres.2009.06.011. Epub 2009 Jul 9.

Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.

Eur J Haematol. 2010 Jul;85(1):86-7. doi: 10.1111/j.1600-0609.2010.01458.x. Epub 2010 Apr 16.

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.

Lancet Oncol. 2007 Jul;8(7):658-60. doi: 10.1016/S1470-2045(07)70206-1.

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7.

A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14.

Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.

Am J Hematol. 2008 Mar;83(3):175-7. doi: 10.1002/ajh.21136.

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.

Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

Ann Hematol. 2023 May;102(5):1279-1280. doi: 10.1007/s00277-023-05187-5. Epub 2023 Mar 22.

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.

Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28.

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?

Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021062. doi: 10.4084/MJHID.2021.062. eCollection 2021.

Emergence of Chronic Myeloid Leukemia in a -V617F Polycythemia Vera.

J Hematol. 2020 Apr;9(1-2):23-29. doi: 10.14740/jh591. Epub 2020 Apr 23.

Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.

World J Clin Cases. 2019 May 6;7(9):1087-1092. doi: 10.12998/wjcc.v7.i9.1087.

Coexistence of -positive chronic myeloid leukemia and -mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.

Blood Res. 2019 Mar;54(1):77-79. doi: 10.5045/br.2019.54.1.77. Epub 2019 Mar 21.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验